2022-Ra-722-Esgo Phase 2 Study Assessing the Efficacy of Adding Al3818 (Catequentinib Dihydrochloride, Anlotinib Hydrochloride) to Chemotherapies in Subjects with Platinum Resistant Ovarian Carcinoma
AuthID
P-00Y-VYN
P-00Y-VYN